INVEX Therapeutics Ltd (IXC) - Total Liabilities

Latest as of June 2026: AU$153.47K AUD ≈ $108.59K USD

Based on the latest financial reports, INVEX Therapeutics Ltd (IXC) has total liabilities worth AU$153.47K AUD (≈ $108.59K USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check INVEX Therapeutics Ltd liquidity resilience to evaluate the company's liquid asset resilience ratio.

INVEX Therapeutics Ltd - Total Liabilities Trend (2019–2026)

This chart illustrates how INVEX Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of INVEX Therapeutics Ltd.

INVEX Therapeutics Ltd Competitors by Total Liabilities

The table below lists competitors of INVEX Therapeutics Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
London Security Plc LSE:LSC	UK	GBX53.59 Million
Kelso Technologies Inc TO:KLS	Canada	CA$1.62 Million
Protektor S.A. WAR:PRT	Poland	zł39.39 Million
Avant Brands Inc TO:AVNT	Canada	CA$24.88 Million
JPMorgan Indian Inv Trust LSE:JII	UK	GBX24.00 Million
Pantera Lithium Ltd AU:PFE	Australia	AU$8.20 Million
Mitra International Resources JK:MIRA	Indonesia	Rp87.64 Billion
Polar Capital Global Healthcare Trust plc LSE:PCGH	UK	GBX40.91 Million

Liability Composition Analysis (2019–2026)

This chart breaks down INVEX Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See INVEX Therapeutics Ltd (IXC) net asset quality to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	26.48	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.04	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.04	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how INVEX Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for INVEX Therapeutics Ltd (2019–2026)

The table below shows the annual total liabilities of INVEX Therapeutics Ltd from 2019 to 2026.

Year	Total Liabilities	Change
2026-06-30	AU$153.47K ≈ $108.59K	-30.43%
2025-06-30	AU$220.59K ≈ $156.08K	-48.89%
2024-06-30	AU$431.63K ≈ $305.41K	-72.55%
2023-06-30	AU$1.57 Million ≈ $1.11 Million	+56.58%
2022-06-30	AU$1.00 Million ≈ $710.55K	+52.47%
2021-06-30	AU$658.61K ≈ $466.01K	-67.32%
2020-06-30	AU$2.02 Million ≈ $1.43 Million	+115.43%
2019-06-30	AU$935.49K ≈ $661.92K	--

About INVEX Therapeutics Ltd

AU:IXC Australia Biotechnology

Market Cap

$5.58 Million

AU$7.89 Million AUD

Market Cap Rank

#28475 Global

#1497 in Australia

Share Price

AU$0.11

Change (1 day)

-8.70%

52-Week Range

AU$0.09 - AU$0.16

All Time High

AU$1.67